Probiotics nudge cholesterol down, but only by a little

Unfavourable blood lipids, including high triglycerides, total cholesterol and LDL cholesterol, are a major risk factor for cardiovascular and metabolic disease. Probiotics have long been proposed as a gentle way to nudge these numbers, with several plausible mechanisms suggested: bile salt hydrolase activity, direct assimilation of cholesterol by bacteria, conversion of cholesterol into coprostanol, effects on host genes governing lipid metabolism, and production of short-chain fatty acids. What has been missing is clarity on how large and how consistent any effect really is, which is exactly what this pooled analysis set out to measure.

The researchers systematically searched PubMed, Embase, Scopus and the Cochrane Library up to February 2025 for randomised controlled trials of probiotic interventions that reported serum lipid outcomes. They found 155 eligible trials covering 9,906 participants, making this one of the larger pooled analyses in the field. Results were combined using a random-effects model, which allows for genuine differences between studies, and expressed as average differences between probiotic and comparison groups across four outcomes: triglycerides, total cholesterol, LDL cholesterol and HDL cholesterol.

Probiotic supplementation improved all four lipid measures, but modestly. Triglycerides fell by an average of 10.83 mg/dL, total cholesterol by 8.46 mg/dL, and LDL cholesterol by 5.83 mg/dL, while HDL cholesterol, the so-called good cholesterol, rose by 1.28 mg/dL. Every one of these shifts was statistically significant, reflecting the sheer size of the evidence base. In absolute terms, though, these are small movements: enough to register on a blood panel, not enough to transform a poor lipid profile on their own.

This analysis firms up a long-suspected pattern: across many strains, doses and populations, probiotics tilt blood lipids in a favourable direction, and the authors position them as an adjunctive approach to managing dyslipidaemia rather than a treatment in their own right. The open questions are practical ones. Trials varied widely in the strains and formulations used, and a pooled average cannot say which specific products, doses or durations drive the benefit, nor how probiotics compare with or add to dietary change and established lipid-lowering treatment.

If your cholesterol or triglycerides run high, this is a reason to view probiotics as a plausible small assist rather than a solution. The average improvements across 9,906 trial participants were real but modest, and nothing in this analysis identifies which strain or product delivers them. Lipid management typically involves diet, activity and sometimes medication, and this evidence casts probiotics as a supporting player alongside those rather than a replacement for any of them. For anyone already taking a probiotic for gut reasons, a small lipid benefit may simply come along for the ride.